Lexicon Phase 2 data: clinically significant benefits in diabetic peripheral neuropathic pain

 Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP)

Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexicon’s dose-ranging Phase 2b PROGRESS trial, currently enrolling patients

https://www.globenewswire.com/news-release/2024/06/19/2901068/0/en/Data-From-Lexicon-s-RELIEF-DPN-1-Phase-2-Study-of-LX9211-Published-Today-in-Diabetes-Care-a-Peer-Reviewed-Journal-of-the-American-Diabetes-Association.html